Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1.

  title={Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1.},
  author={Francisco Vega and Leonard Jeffrey Medeiros and Carlos E Bueso-Ramos and Patricia Berm{\'u}dez and Roberto N. Miranda},
  journal={American journal of clinical pathology},
  volume={144 3},
OBJECTIVES This session of the 2013 Society for Hematopathology/European Association for Haematopathology Workshop was dedicated to tumors currently included in the World Health Organization (WHO) classification category of myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. METHODS We use the cases submitted to this session to review the clinicopathologic and genetic spectrum of these neoplasms, methods for their diagnosis, and issues related to… 

Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.

Accurate diagnosis and classification of this category of myeloid/lymphoid neoplasms with eosinophilia and PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2 rearrangements has important therapeutic implications.

Synchronous T lymphoblastic lymphoma and myeloid neoplasm with PDGFRA rearrangement

A rare but distinct entity ‘myeloid/lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA’ has first been described in 2008 and then in 2016 World Health Organization (WHO) classification

Myeloid and Lymphoid Neoplasms with Eosinophilia

Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1 were first formally accepted as a set of entities in the 2008 edition of the World Health Organization’s

Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.

These new NCCN Guidelines include recommendations for the diagnosis, staging, and treatment of any one of the myeloid/lymphoid neoplasms with eosinophilia (MLN-Eo) and a TK fusion gene included in the 2017 WHO Classification, as well as MLN- Eo and a FLT3 or ABL1 rearrangement.

Clinical, hematological and cytogenetic profile in fibroblast growth factor receptor 1 rearranged hematoloymphoid malignancies

Clinical, biochemical, molecular and cytogenetic features observed in these cases are described and the CNTRL/FGFR1 fusion as identified by conventional cytogenetics and confirmed by molecular studies are described.

The power of the partner: defying expectations in a case of a myeloproliferative neoplasm with FGFR1 rearrangement

A case of a man with an FGFR1-rearranged MPN who continues to be remarkably well eight years after diagnosis, with no mutations in JAK2 exons 12-14, CALR, MPL, CSF3R, and RUNX1.

Fibroblast growth factor receptor-1 associated myeloproliferative neoplasm and T-lymphoblastic lymphoma

The case of a 30-year-old-woman who was diagnosed with T-lymphoblastic lymphoma from lymph node biopsy and myeloproliferative neoplasm with eosinophilia from bone marrow studies is presented to create awareness among physicians about this rare condition associated with dual malignancies.

Systematic use of fluorescence in‐situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms

This work aims to develop a broader strategy for screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms with high sensitivity to tyrosine kinase inhibitors.

Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA , PDGFRB , FGFR1, or t(8;9)(p22;p24.1); PCM1-JAK2

This chapter will further divulge additional details regarding this heterogeneous group of neoplasms including description of various fusion partners with PDGFRA, PDGFRB, and FGFR1.

Multiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11)

It is proved that MYO18A-PDGFRB fusions are recurrent genetic aberrations involved in MPNs, and multiple fusion transcripts with novel breakpoints are identified.



Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate

Treatment with imatinib resulted in complete and durable clinical, hematological, and molecular remission within 3 months after starting treatment, and a 2‐year‐old female with a myeloid neoplasm associated with eosinophilia and rearrangement of PDGFRA was reported.

Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

The prognosis is outstanding, acquired resistance is exceedingly rare, but ongoing imatinib treatment is likely required to prevent relapse, and their recognition is critical because of the availability of highly effective molecularly targeted therapy.

t(8;13)-positive Bilineal Lymphomas: Report of 6 Cases

The morphologic and immunophenotypic features of 6 cases of t(8;13)-positive bilineal lymphoma of mixed T-cell and myeloid lineage, which present as lymphoma, are described and it is believed that they likely arise from an early hematopoietic cell with potential to differentiate along T- cell andmyeloid pathways.

Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA‐positive hypereosinophilic syndrome

Results suggest that the mutation arises in a pluripotential haematopoietic progenitor cell capable of giving rise to multiple lineages in myeloproliferative hypereosinophilic syndrome.

Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia

The utility of screening forPDGFRA kinase domain overexpression in patients with IHES is demonstrated and a third PDGFRA fusion partner in chronic myeloproliferative disorders is identified.

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma

All eosinophilia-associated hematological malignancies should be screened for the presence of the FIP1L1-PDGFRA fusion gene as they are excellent candidates for treatment with tyrosine kinase inhibitors even if they present with an aggressive phenotype such as AML.

PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

Tumors expressing KIT or PDGFRA oncoproteins were indistinguishable with respect to activation of downstream signaling intermediates and cytogenetic changes associated with tumor progression, suggesting KIT and PDGFra mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs.

Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias

FIP1L1-PDGFRA (+) CEL emerges as a homogeneous clinicobiological entity, where imatinib can induce molecular remission, and while RT-PCR and interphase FISH are equally valid diagnostic tools, the role of marrow biopsy in diagnosis and of RQ- PCR in disease and therapy monitoring needs further evaluation.

Myeloproliferative Disorders with Translocations of Chromosome 5q31–35: Role of the Platelet-Derived Growth Factor Receptor Beta

Clinically, most patients present with a myeloproliferative disorder (MPD) with eosinophilia, eOSinophilic leukemia or chronic myelomonocytic leukemia and thus fall into the broader category of myelofiltration disorders/myelodysplastic syndromes (M PD/MDS).